Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486782 | 0.98 | CA14 (0.35) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL6485797 | 0.97 | EPHX1 (0.35) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL4914499 | 0.95 | CA14 (0.37) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL4711748 | 0.90 | CA14 (0.39) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL2660428 | 0.89 | CA14 (0.34) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL1240735 | 0.89 | CA14 (0.34) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL10323856 | 0.89 | CA14 (0.34) | CA14DPP4BTKASGR1HSD11B1 | |
| SCHEMBL1920876 | 0.88 | SLC6A4 (0.34) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL1067463 | 0.87 | EPHX1 (0.36) | CA14DPP4PYGLL3MBTL1HSD11B1 | |
| SCHEMBL20408347 | 0.86 | CA14 (0.44) | CA14TDP1PYGLPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| WO-2006110626-A1 | AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-6903107-B1 | Serine protease inhibitor | AKZO NOBEL N.V. (NL) | 2005-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | CA14 3634/4885TDP1 4697/4885HDAC1 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.